Curated News
By: NewsRamp Editorial Staff
November 12, 2025
Annovis Bio Reports Major Alzheimer's Trial Progress and Promising Biomarker Data
TLDR
- Annovis Bio's Phase 3 Alzheimer's trial activation and promising biomarker data position the company for a competitive advantage in the neurodegenerative disease market.
- Annovis Bio activated all 84 sites in its Phase 3 Alzheimer's study and demonstrated buntanetap's mechanism through biomarker data showing reduced inflammation and neurodegeneration.
- Annovis Bio's Alzheimer's treatment development offers hope for improving patient quality of life and advancing care for neurodegenerative diseases worldwide.
- Annovis Bio secured patent protection through 2046 for buntanetap while reporting biomarker data showing strong reductions in inflammation and neurodegeneration.
Impact - Why it Matters
This development represents a significant advancement in the fight against neurodegenerative diseases that affect millions worldwide. Alzheimer's and Parkinson's diseases currently have limited treatment options, and most available therapies only address symptoms rather than modifying the underlying disease progression. The promising biomarker data showing reductions in inflammation and neurodegeneration suggests buntanetap could potentially slow or halt disease progression, which would represent a breakthrough in neurological treatment. For patients and families affected by these devastating conditions, successful development of disease-modifying therapies could mean preserved cognitive function, maintained independence, and improved quality of life. The progress toward NDA submission also signals potential near-term availability of new treatment options, while the extended patent protection through 2046 ensures long-term commercial viability if approved.
Summary
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, reported significant progress in its neurodegenerative disease pipeline during the third quarter of 2025. The company achieved full activation of all 84 clinical sites in its pivotal Phase 3 Alzheimer's study (NCT06709014) with steady enrollment across the United States. Under the leadership of President and CEO Maria Maccecchini, Ph.D., Annovis announced promising biomarker data from its Phase 2/3 Alzheimer's trial showing strong reductions in inflammation and neurodegeneration, highlighting buntanetap's disease-modifying potential. The company also strengthened its intellectual property position by transferring all patents to the new crystal form of buntanetap with protection extending through 2046, published supportive pharmacokinetic data, and appointed veteran finance executive Mark Guerin as CFO. As Maccecchini stated, "Every element is now aligned as we move toward our data readouts—the final step before an NDA submission."
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in Alzheimer's disease and Parkinson's disease through innovative therapies that aim to improve patient outcomes and quality of life. The company maintains an active presence across multiple platforms including their official website and social media channels on LinkedIn, YouTube, and X. This progress update was distributed through the InvestorBrandNetwork's Dynamic Brand Portfolio, which provides advanced wire-grade press release syndication and comprehensive corporate communications solutions through its InvestorWire platform. The news release emphasized that all elements are now aligned as the company moves toward critical data readouts that represent the final step before submitting a New Drug Application to regulatory authorities.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio Reports Major Alzheimer's Trial Progress and Promising Biomarker Data
